SINGAPORE: AstraZeneca Plc plans to build a US$1.5 billion manufacturing facility in Singapore to make antibody-drug conjugates as the UK drugmaker pushes to beef up its ability to produce the next-generation cancer treatments.
The plant will be Astra’s first drug-conjugate facility to produce the medicines from start to finish and is part of a global shift by drugmakers to ensure local manufacturing capacity for their products.
The facility is planned to be ready to open in 2029, with Astra saying in a statement Monday it will be designed to emit zero carbon from the start.